共 50 条
- [1] Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 studyJOURNAL OF CROHNS & COLITIS, 2022, 16 : I026 - I027Danese, S.Panaccione, R.Rubin, D. T.Sands, B. E.Reinisch, W.D'Haens, G.Panes, J.Gonzalez, S.Weisel, K.Sahoo, A.Frustaci, M. E.Yang, Z.Sandborn, W. J.Afzali, A.Hisamatsu, T.Andrews, J. M.Feagan, B.
- [2] Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: Week 48 Analyses from the Phase 2 GALAXI 1 StudyARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3656 - 3660Danese, SilvioPanaccione, RemoRubin, David T.Sands, Bruce E.Reinisch, WalterD'Haens, GeertPanes, JulianGonzalez, SusanaWeisel, KathleenSahoo, AparnaFrustaci, Mary EllenYang, ZijiangSandborn, William J.Afzali, AnitaHisamatsu, TadakazuAndrews, Jane M.Feagan, Brian G.
- [3] Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the Phase 2 GALAXI-1 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 127 - 129Danese, S.Panaccione, R.Rubin, D. T.Sands, B. E.Reinisch, W.D'Haens, G.Panes, J.Gonzalez, S.Weisel, K.Sahoo, A.Frustaci, M. E.Yang, Z.Sandborn, W. J.Afzali, A.Hisamatsu, T.Andrews, J. M.Feagan, B. G.
- [4] Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the Phase 2 GALAXI 1 StudyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 118 - 119D'Haens, G.Afzali, A.Filip, R.Rolim, A.Terry, N.Salese, L.Sahoo, A.Frustaci, M. E.Yang, Z.Andrews, J.Danese, S.Hisamatsu, T.
- [5] Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 studyJOURNAL OF CROHNS & COLITIS, 2023, 17 : 601 - 602D'Haens, G.Afzali, A.Filip, R.Rolim, A.Terry, N. A.Salese, L.Sahoo, A.Frustaci, M. E.Yang, Z.Andrews, J. M.Danese, S.Hisamatsu, T.
- [6] CORTICOSTEROID-FREE CLINICAL REMISSION RATES WITH GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2B GALAXI 1 STUDYGASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1087Afzali, AnitaD'Haens, GeertFilip, RafalRolim, AlexanderTerry, Natalie A.Salese, LeonardoSahoo, AparnaFrustaci, Mary Ellen S.Yang, ZijiangAndrews, Jane M.Danese, SilvioHisamatsu, Tadakazu
- [7] EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIESGASTROENTEROLOGY, 2024, 166 (05)Panaccione, RemoDanese, SilvioFeagan, Brian G.D'Haens, GeertAfzali, AnitaReinisch, WalterPanes, JulianRubin, David T.Andrews, Jane M.Hisamatsu, TadakazuTerry, Natalie A.Salese, LeonardoVan Rampelbergh, RianFrustaci, Mary Ellen S.Yang, ZijiangJohanns, JewelWan, Kitty Y.Yee, JacquelineSands, Bruce E.
- [8] Efficacy And Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results of the Galaxi 2 & 3 Phase 3 StudiesARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2312 - 2318Panaccione, RemoDanese, SilvioFeagan, Brian G.D'Haens, GeertAfzali, AnitaReinisch, WalterPanes, JulianRubin, David T.Andrews, JaneHisamatsu, TadakazuTerry, Natalie A.Salese, LeonardoVan Rampelbergh, RianFrustaci, Mary EllenYang, ZijiangJohanns, JewelWan, Kitty Yuen YiYee, JacquelineSands, Bruce E.
- [9] Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn's Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S626 - S626Panaccione, RemoAfzali, AnitaD'Haens, Geert R.Salese, LeonardoTerry, Natalie A.Sahoo, AparnaFrustaci, Mary EllenYang, ZijiangZittan, EranDanese, SilvioHisamatsu, Tadakazu
- [10] Effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 108 - 109Sands, B.Danese, S.Andrews, J.Weisel, K.Chan, D.Johanns, J.Frustaci, M. E.Yang, Z.Cunningham, M.Ghanem, L.Panaccione, R.Afzali, A.Sandborn, W.